Servicios Personalizados
Revista
Articulo
Indicadores
- Citado por SciELO
- Accesos
Links relacionados
- Similares en SciELO
Compartir
Revista alergia México
versión On-line ISSN 2448-9190
Resumen
LOPEZ-ROCHA, Eunice Giselle; HERNANDEZ-MONTOYA, Gerardo; RODRIGUEZ-PESINA, Alberto Hernán y RODRIGUEZ-MIRELES, Karen Alicia. De-sensitization to allopurinol in a patient with tophi gout. Rev. alerg. Méx. [online]. 2018, vol.65, n.3, pp.316-320. ISSN 2448-9190. https://doi.org/10.29262/ram.v65i3.369.
Background:
Allopurinol is a xanthine oxidase inhibitor used in the treatment of patients with gout. Approximately 2% of patients are aff ected by adverse reactions to this drug. Severity ranges from mild rashes to severe reactions in up to 0.4% of cases. De-sensitization is carried out by administering increasing doses of the drug.
Case report:
Thirty-year old man diagnosed with hypercholesterolemia and hypertriglyceridemia
treated with bezafi brate and pravastatin, systemic arterial hypertension treated with losartan and a 10-year history of hyperuricemia with gout. Tophi were found in metacarpophalangeal joints and elbows. Treatment was started with allopurinol 300 mg/day. Two weeks later, he experienced facial erythema with itching and maculopapular lesions on the malar region 1 hour after the medication was ingested. An outpatient drug de-sensitization protocol was initiated, starting with 5 mg, and with gradual dose increases every 4 to 5 days for 59 days until the desired maintenance dose (300 mg) was reached.
Conclusions:
Experience shows that de-sensitization to allopurinol is a safe alternative when there is hypersensitivity and treatment with this drug is required.
Palabras llave : Tophi gout; Uric acid; De-sensitization to allopurinol.